Should I buy or sell OncoCyte stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OCX shares. View OCX analyst ratings or view top-rated stocks .

What is OncoCyte's stock price target for 2024?

3 analysts have issued 1 year price objectives for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $3.87 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts .

How have OCX shares performed in 2023?

OncoCyte's stock was trading at $6.4180 at the start of the year. Since then, OCX shares have decreased by 47.8% and is now trading at $3.35. View the best growth stocks for 2023 here .

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our OCX earnings forecast .

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($1.52) by $0.95. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.40 million. OncoCyte had a negative net margin of 3,923.58% and a negative trailing twelve-month return on equity of 77.26%.

When did OncoCyte's stock split?

OncoCyte's stock reverse split on the morning of Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV) , Biocept (BIOC) , Aurora Cannabis (ACB) , CymaBay Therapeutics (CBAY) , Fulcrum Therapeutics (FULC) , Xeris Biopharma (XERS) , Zynerba Pharmaceuticals (ZYNE) , AbbVie (ABBV) , Acasti Pharma (ACST) and Aileron Therapeutics (ALRN) .

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (8.71%), Defender Capital LLC. (1.39%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews. View institutional ownership trends .

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

OncoCyte Stock Price, News & Analysis (NASDAQ:OCX)

$3.16

-0.68 (-17.71%)

(As of 01:34 PM ET)

Compare

Today's Range: $2.83
▼
$3.75
50-Day Range: $2.08
▼
$4.26
52-Week Range: $2.08
▼
$10.00

Volume: 30,293 shs
Average Volume: 18,591 shs
Market Capitalization: $26.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.87

OncoCyte MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 15.4% Upside
$3.87 Price Target
Short Interest: Bearish
2.67% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.78
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.59) to ($3.01) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

929th out of 960 stocks

Diagnostic Substances Industry

9th out of 10 stocks

2.3

Analyst's Opinion

Consensus Rating
OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.87, OncoCyte has a forecasted upside of 15.4% from its current price of $3.35.
Amount of Analyst Coverage
OncoCyte has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.67% of the float of OncoCyte has been sold short.
Short Interest Ratio / Days to Cover
OncoCyte has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.
Change versus previous month
Short interest in OncoCyte has recently decreased by 1.07%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
OncoCyte does not currently pay a dividend.
Dividend Growth
OncoCyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OCX.

3.2

News and Social Media Coverage

News Sentiment
OncoCyte has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for OncoCyte this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added OncoCyte to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OncoCyte insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.94% of the stock of OncoCyte is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OncoCyte are expected to decrease in the coming year, from ($1.59) to ($3.01) per share.
Price to Book Value per Share Ratio
OncoCyte has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OncoCyte Stock (NASDAQ:OCX)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OCX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OCX Stock News Headlines

December 8, 2023 | americanbankingnews.com

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

December 6, 2023 | finance.yahoo.com

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

December 8, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

November 18, 2023 | morningstar.com

OncoCyte Corp OCX

November 10, 2023 | finance.yahoo.com

OncoCyte Corporation (NASDAQ:OCX) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon

November 9, 2023 | finance.yahoo.com

Oncocyte Reports Third Quarter 2023 Financial Results

November 3, 2023 | finance.yahoo.com

Oncocyte to Announce Third Quarter 2023 Financial Results

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

September 18, 2023 | finanznachrichten.de

Oncocyte Corporation: Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

September 18, 2023 | finance.yahoo.com

Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

September 6, 2023 | finance.yahoo.com

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023 | finanznachrichten.de

Oncocyte Corporation: Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

August 28, 2023 | finance.yahoo.com

Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

August 24, 2023 | nasdaq.com

Benchmark Maintains Oncocyte (OCX) Speculative Buy Recommendation

August 15, 2023 | msn.com

Piper Sandler Maintains Oncocyte (OCX) Neutral Recommendation

August 11, 2023 | msn.com

Needham Maintains Oncocyte (OCX) Buy Recommendation

August 10, 2023 | finanznachrichten.de

Oncocyte Corporation: Oncocyte Reports Second Quarter 2023 Financial Results

August 10, 2023 | finance.yahoo.com

Oncocyte Reports Second Quarter 2023 Financial Results

August 9, 2023 | finance.yahoo.com

Oncocyte Regains Compliance With Nasdaq Listing Requirements

August 9, 2023 | finanznachrichten.de

Oncocyte Corporation: Oncocyte Regains Compliance With Nasdaq Listing Requirements

August 8, 2023 | finance.yahoo.com

Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

August 3, 2023 | finance.yahoo.com

Oncocyte To Announce Second Quarter 2023 Financial Results

August 2, 2023 | msn.com

Oncocyte (OCX) Price Target Increased by 1900.00% to 7.14

July 25, 2023 | finance.yahoo.com

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

July 25, 2023 | finanznachrichten.de

Oncocyte Corporation: Oncocyte Announces 1-For-20 Reverse Stock Split

July 24, 2023 | finance.yahoo.com

Oncocyte Announces 1-For-20 Reverse Stock Split

See More Headlines

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OCX
CUSIP: N/A
CIK: 1642380
Web: oncocyte.com
Phone: (949) 409-7600
Fax: 510-521-3389
Employees: 75
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.87
High Stock Price Target: $5.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +5.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,900,000.00
Net Margins: -3,923.58%
Pretax Margin: -1,427.20%
Return on Equity: -77.26%
Return on Assets: -33.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.11
Quick Ratio: 2.11

Sales & Book Value

Annual Sales: $1.46 million
Price / Sales: 20.67
Cash Flow: $0.84 per share
Price / Cash Flow: 4.34
Book Value: $5.78 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 8,261,000
Free Float: 8,101,000
Market Cap: $30.24 million
Optionable: Optionable
Beta: 1.81

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Joshua Riggs (Age 40)
President, CEO & Director
Comp: $373.2k
Mr. James Liu (Age 27)
Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer
Comp: $192.48k
Dr. Ekkehard Schutz M.D.
Ph.D., Chief Science Officer
Mr. Yuh-Min Chiang Ph.D.
Senior Vice President of R&D and Product Development
Ms. Sandra O'Donald
Senior Vice President of Business Operations
Dr. Michael D. West Ph.D. (Age 70)
Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.
Peter Hong
Secretary
Ms. Sara Riordan
Director of Medical Education

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OCX Stock Analysis - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OCX shares.
View OCX analyst ratings or view top-rated stocks.
What is OncoCyte's stock price target for 2024?: 3 analysts have issued 1 year price objectives for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $3.87 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts price targets for OCX or view top-rated stocks among Wall Street analysts.
How have OCX shares performed in 2023?: OncoCyte's stock was trading at $6.4180 at the start of the year. Since then, OCX shares have decreased by 47.8% and is now trading at $3.35.
View the best growth stocks for 2023 here.
When is OncoCyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our OCX earnings forecast.
How were OncoCyte's earnings last quarter?: OncoCyte Co. (NASDAQ:OCX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($1.52) by $0.95. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.40 million. OncoCyte had a negative net margin of 3,923.58% and a negative trailing twelve-month return on equity of 77.26%.

When did OncoCyte's stock split?: OncoCyte's stock reverse split on the morning of Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of OncoCyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).
Who are OncoCyte's major shareholders?: OncoCyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (8.71%), Defender Capital LLC. (1.39%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends.
How do I buy shares of OncoCyte?: Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OCX) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial